Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,725.16
(
-0.30%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.26
(
3.45%
)
Bitcoin
70,182.15
(
-1.49%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rwdm post# 164925

Thursday, 11/14/2013 12:51:43 PM

Thursday, November 14, 2013 12:51:43 PM

Post# of 257257
(MNTA)—MYL needs to get generic Copaxone (and generic Advair) approved in the US to hit the very aggressive 2018 targets the company has given to investors for sales and EPS. If MYL fails to get these products approved, the shortfall would presumably have to be made up via one or more acquisitions that are accretive to EPS.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now